-
.jpg)
.jpg)
- SITC 2022 POSTER
- Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent andin combination with pembrolizumab in patients with advanced and/or metastatic solid tumors
-
.jpg)
.jpg)
- Yong Min Oh VP,
Webinar Presentation invited by Merck
- Yong Min Oh VP,
-
.jpg)
.png)
- Participate in ASCO 2022
-
.jpg)
.jpg)
- Korea excellent patent grand prize
-
(1).jpg)
.jpg)
- Certificate of IP Management Enterprise
- Korean Intellectual Property Office
-
.jpg)
- SITC 2021 POSTER
- A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a Pembrolizumab, Lenvatinib or Local RT in advanced solud tumors (KEYNOTE-B59)
-
.jpg)
.jpg)
- Certificate of Excellent Enterprise for Employee's Invention Compensation
- Korean Intellectual Property Office
-
.jpg)
.jpg)
- Selection Top 100 National R&D performances in 2020
- GI-101, Selection Top 100 National R&D performances in 2020 from Ministry of Science and ICT
-
.jpg)
.jpg)
- Korea Bio pharmaceuticals award
- Awardee of 'Global Challenger' in Korea Bio pharmaceuticals (GI-301)
-
.jpg)
.jpg)
- AACR 2021 POSTER
- Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeuticantibody candidate with bispecific immuno-oncology target
